Skip to main content

The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms.

Panattoni LE.
J Health Econ. 30(1):126-45. doi: 10.1016/j.jhealeco.2010.09.004. Epub 2010 Oct 8.

You're leaving our site

The website you have selected is an external one located on another server. This website may contain links to third party sites. These links are provided for convenience purposes and are not under the control of Sutter Health. Do you wish to continue?